U.S. markets closed
  • S&P 500

    4,280.15
    +72.88 (+1.73%)
     
  • Dow 30

    33,761.05
    +424.38 (+1.27%)
     
  • Nasdaq

    13,047.19
    +267.27 (+2.09%)
     
  • Russell 2000

    2,016.62
    +41.36 (+2.09%)
     
  • Crude Oil

    91.88
    -2.46 (-2.61%)
     
  • Gold

    1,818.90
    +11.70 (+0.65%)
     
  • Silver

    20.83
    +0.49 (+2.39%)
     
  • EUR/USD

    1.0257
    -0.0068 (-0.66%)
     
  • 10-Yr Bond

    2.8490
    -0.0390 (-1.35%)
     
  • GBP/USD

    1.2139
    -0.0064 (-0.52%)
     
  • USD/JPY

    133.4800
    +0.4810 (+0.36%)
     
  • BTC-USD

    24,626.72
    +664.21 (+2.77%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • Nikkei 225

    28,546.98
    +727.65 (+2.62%)
     

This Analyst Thinks 89Bio's Pegozafermin Data Has Exceeded Expectations

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • In June, 89bio Inc (NASDAQ: ETNBannounced topline results from the ENTRIGUE Phase 2 proof-of-concept study of pegozafermin for severe hypertriglyceridemia (SHTG).

  • SVB Leerink views these results as 'strong' and says they provide a clear win for the company as all doses of pegoza demonstrated statistically significant and clinically meaningful reductions in triglycerides, exceeding KOL expectations ahead of the results.

  • The analysts say that pegoza's safety/tolerability profile continues to look favorable vs. Akero Therapeutics Inc's (NASDAQ: AKRO) efruxifermin, with lower rates of GI toxicity (diarrhea, nausea, vomiting) and no apparent CNS/tremor signal.

  • SVB has updated its model to reflect a higher probability of success (70% from 35%) and higher peak sales (~$700 million from ~$660 million) in SHTG based on the Phase 2 results and the latest equity offering.

  • The analyst has lowered the price target to $29 from $50 and reiterates the Out-Perform rating.

  • "Overall, we continue to view pegozafermin as a potentially best-in-class FGF21 analog, based on its competitive efficacy profile — now shown across multiple indications — and emerging differentiation on safety/ tolerability," SVB wrote.

  • Price Action: ETNB shares are down 4.48% at $3.41 during the market session on the last check Monday.

Latest Ratings for ETNB

Date

Firm

Action

From

To

Dec 2021

HC Wainwright & Co.

Initiates Coverage On

Buy

Oct 2021

Cantor Fitzgerald

Assumes

Overweight

Aug 2021

RBC Capital

Maintains

Outperform

View More Analyst Ratings for ETNB

View the Latest Analyst Ratings

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.